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HoOBJECTIVES The aim of this study was to determine the lowest optimal tissue plasminogen activator (tPA) dose and
delivery duration using ultrasound-facilitated catheter-directed thrombolysis (USCDT) for the treatment of acute
intermediate-risk (submassive) pulmonary embolism.
BACKGROUND Previous trials of USCDT used tPA over 12 to 24 h at doses of 20 to 24 mg for acute pulmonary
embolism.
METHODS Hemodynamically stable adults with acute intermediate-risk pulmonary embolism documented by computed
tomographic angiography were randomized into this prospective multicenter, parallel-group trial. Patients received
treatment with 1 of 4 USCDT regimens. The tPA dose ranged from 4 to 12 mg per lung and infusion duration from 2 to 6 h.
The primary efﬁcacy endpoint was reduction in right ventricular–to–left ventricular diameter ratio by computed tomo-
graphic angiography. A major secondary endpoint was embolic burden by reﬁned modiﬁed Miller score, measured on
computed tomographic angiography 48 h after initiation of USCDT.
RESULTS One hundred one patients were randomized, and improvements in right ventricular–to–left ventricular diameter
ratio were as follows: arm 1 (4 mg/lung/2 h), 0.40 (24%; p ¼ 0.0001); arm 2 (4 mg/lung/4 h), 0.35 (22.6%; p¼ 0.0001);
arm 3 (6mg/lung/6 h), 0.42 (26.3%; p¼0.0001); and arm 4 (12mg/lung/6 h), 0.48 (25.5%; p¼0.0001). Improvement in
reﬁned modiﬁed Miller score was also seen in all groups. Four patients experienced major bleeding (4%). Of 2 intracranial
hemorrhage events, 1 was attributed to tPA delivered by USCDT.
CONCLUSIONS Treatment with USCDT using a shorter delivery duration and lower-dose tPA was associated
with improved right ventricular function and reduced clot burden compared with baseline. The major bleeding rate
was low, but 1 intracranial hemorrhage event due to tPA delivered by USCDT did occur. (J Am Coll Cardiol Intv 2018;11:1401–10)
© 2018 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).N 1936-8798 https://doi.org/10.1016/j.jcin.2018.04.008
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CTA = computed tomographic
angiography
ICH = intracranial hemorrhage
ITT = intention to treat
LV = left ventricular
mPP = modiﬁed per protocol
PE = pulmonary embolism
RV = right ventricular
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1402T hrombolysis has been studied inintermediate-risk (submassive) pul-monary embolism (PE), but concern
over intracranial hemorrhage (ICH) with sys-
temic thrombolysis (1,2) has resulted in
limited use of this approach except in high-
risk (massive) PE. Bleeding complications
with systemic thrombolysis have also gener-
ated interest in alternative therapies with
lower bleeding risk. Ultrasound-facilitated
catheter-directed thrombolysis (USCDT) is a
form of pharmacomechanical thrombolysis
(3,4) that uses the energy transmitted by
high-frequency (2 to 3 MHz), low-power ul-
trasound waves. In vitro and in animal
models, this technique has been shown to
separate ﬁbrin strands, increasing thrombus
surface area and making more plasminogenactivator receptor sites available for facilitating
thrombolysis (5).SEE PAGE 1411The EkoSonic Endovascular System (Ekos/BTG,
Bothell, Washington) ultrasound device has been
described previously (6,7). Prior trials of USCDT in
acute intermediate-risk PE evaluated infusion dura-
tions of 12 to 24 h. In most cases, both the right and
left pulmonary arteries were treated (6,7).
In intermediate-risk PE, the randomized controlled
ULTIMA (Ultrasound Accelerated Thrombolysis of
Pulmonary Embolism) trial demonstrated that right
ventricular (RV)–to–left ventricular (LV) diameter ra-
tio is improved at 24 h with USCDT compared with
anticoagulation alone and with no major bleeding (6).
In the SEATTLE II (A Prospective, Single-Arm, Multi-
Center Trial of EkoSonic Endovascular System and
Activase for Treatment of Acute Pulmonary Embo-
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received December 1, 2017; revised manuscript received March 2RV-to-LV diameter ratio improvement at 48 h
compared with baseline in predominantly
intermediate-risk PE and a smaller population of pa-
tients with massive PE (21%), with a major bleeding
rate of 10%. There were no ICH events (7). Other
studies have shown an association between the use of
USCDT and signiﬁcant improvement in PA pressure
(p < 0.001), cardiac index (p < 0.001), RV-to-LV
diameter ratio (p < 0.001) (8), and shorter length of
hospital stay (9). This USCDT device was approved by
the U.S. Food and Drug Administration on May 21,
2014, for treatment of acute PE.
We hypothesized that even lower doses of tissue
plasminogen activator (tPA) and shorter durations of
USCDT than were used in prior studies would be
associated with improvement in RV function in this
intermediate-risk population.
METHODS
STUDY DESIGN. The trial (NCT02396758) was
designed by our steering committee with participa-
tion of the sponsor (Ekos/BTG). The 101 trial partic-
ipants were enrolled at 17 centers in the United
States and Europe. Institutional Review Board
approval was obtained at all sites, and written con-
sent was obtained from all patients. Imaging analysis
was conducted by Syntactx (New York, New York).
Statistical support was provided and reviewed
independently in an unblinded manner by Claire
Daugherty (BTG) and Ping-Yu Liu (Liu Associates
Consulting). This was a multicenter, parallel-group
study in which participants were randomly
assigned to 1 of 4 USCDT regimens, varying in
duration and total tPA dose.
STUDY POPULATION. Patients 18 to 75 years of age
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1403for <14 days with normal systolic blood pressure
(>90 mm Hg), RV-to-LV diameter ratio $0.9 on chest
computed tomographic angiography (CTA), and
proximal PE located in at least 1 main or proximal
lobar pulmonary artery. Troponin and brain natri-
uretic protein were obtained but not required for in-
clusion. Major exclusion criteria included stroke or
transient ischemic attack, head trauma, other active
intracranial or intraspinal disease within 1 year, recent
active bleeding from a major organ within 1 month,
major surgery within 7 days of screening, systolic
blood pressure <90 mm Hg or use of vasopressors,
hematocrit <30%, platelet count <100,000/ml, inter-
national normalized ratio >3, creatinine outside the
normal range, and, as of June 8, 2016, any hematologic
disease potentially involving abnormal platelet num-
ber or function. Additional exclusion criteria were
perceived high risk for catastrophic bleeding, history
of heparin-induced thrombocytopenia, catheter-
based pharmacomechanical treatment for PE within
3 days of study enrollment, cardiac arrest requiring
active cardiopulmonary resuscitation, evidence of
irreversible neurological compromise, life
expectancy <1 year, use of thrombolytics or glyco-
protein IIb/IIIa receptor antagonists within 3 days
before USCDT procedure, pregnancy or breastfeeding,
and allergy or hypersensitivity to tPA or iodinated
contrast except for mild to moderate contrast allergies
for which steroid pre-medication can be used. Patients
with active cancer (metastatic, progressive, or treated
within the past 6 months) were excluded; patients
with nonmelanoma primary skin cancer, however,
were eligible.
TREATMENT REGIMENS. Patients were randomized
to 1 of 4 groups (block randomization with block size
4). This was changed to block size 3 after arm 4 was
closed. Subject identiﬁcation information was
entered in the electronic case report form to produce
the randomization assignment. The 4 arms were as
follows: arm 1, USCDT  2 h with tPA infused at 2 mg/
h per catheter (range 4 to 8 mg; 1 vs. 2 lungs); arm 2,
USCDT  4 h with tPA infused at 1 mg/h per catheter
(range 4 to 8 mg; 1 vs. 2 lungs); arm 3, USCDT 6 h with
tPA infused at 1 mg/h per catheter (range 6 to 12 mg;
1 vs. 2 lungs); arm 4, USCDT  6 h with tPA infused
at 2 mg/h per catheter (range 12 to 24 mg; 1 vs. 2
lungs).
All patients received therapeutic anticoagulation;
the heparin dose was reduced to 300 to 500 U/h
during the thrombolytic infusion and increased to full
therapeutic dosing after USCDT. Patients receiving
low–molecular-weight heparin received therapeutic
doses. After the USCDT procedure, the type andduration of anticoagulation were determined by the
responsible physician.
THE USCDT PROCEDURE. The USCDT procedure was
performed in an angiographic suite by interventional
radiologists or cardiologists or vascular surgeons
within 48 h of diagnostic CTA. The 5.2-F infusion
catheter contains 3 lumens, 1 for the inner ultrasound
cable, 1 for drug infusion, and 1 for the coolant
(normal saline). Placement of the Ekos catheter was
guided by ﬂuoroscopy or focused pulmonary arteri-
ography. For unilateral PE in 1 main or proximal lobar
pulmonary artery, 1 catheter was placed in the
involved vessel (these patients received half of the
dose that bilateral patients received). With bilateral
PE in the main or proximal lobar pulmonary arteries,
2 catheters were placed, 1 in each of the involved
vessels. Site of venous access was at the discretion of
the treating physician. Venous access was obtained
using ultrasound guidance. Physicians could use ju-
gular or femoral venous access for placing 1 catheter
or bilateral or ipsilateral femoral venous access for
placing 2 devices in the pulmonary arteries. Treat-
ment began with infusion of tPA and saline coolant at
35 ml/h per catheter. The MicroSonic core of the
EkoSonic device was then activated to deliver low-
energy ultrasound.
DETERIORATION OR NONRESPONSE TO USCDT
PROCEDURE. Cessation of the procedure in favor of
alternative therapy could be undertaken for adverse
events such as recurrent PE, clinical deterioration, or
bleeding. If there was no signiﬁcant clinical or echo-
cardiographic improvement but the patient was clin-
ically stable, investigators were encouraged not to
add additional advanced therapy beyond the USCDT
protocol and simply to resume full anticoagulation.
OUTCOMES: EFFICACY AND SAFETY ENDPOINTS.
The primary efﬁcacy endpoint was change in RV-to-
LV diameter ratio as measured by CTA from baseline
to 48  6 h after the start of USCDT. A secondary ef-
ﬁcacy endpoint was change from baseline in embolic
burden determined by reﬁned modiﬁed Miller score
by chest CTA at 48  6 h after the procedure (Online
Appendix). Although we initially considered deter-
mining Miller score and hemodynamic status by
pulmonary arteriography before and within 4 h after
the end of the USCDT procedure, the protocol was
amended to make these follow-up measurements
optional because of the logistics of returning to the
catheterization laboratory within 4 h after treatment.
The primary safety outcome was frequency of
major bleeding within 72 h after the start of the
USCDT procedure by International Society on
FIGURE 1 Patient Flow and Evolution From ITT to mPP
A total of 101 patients with proven acute intermediate-risk pulmonary embolism (PE) by computed tomographic angiography (CTA) were randomized to 1 of 4
treatment arms at 17 centers in the United States and Europe. Clot burden was assessed by reﬁned modiﬁed Miller score, and right ventricular (RV)/left ventricular (LV)
diameter ratio was measured by CTA in all patients.
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1404Thrombosis and Haemostasis criteria (10): 1) fatal
bleeding; or 2) symptomatic bleeding in a critical area
or organ, such as intracranial, intraspinal, intraocular,
retroperitoneal, intra-articular, pericardial, or intra-
muscular with compartment syndrome; or 3) bleeding
causing a decrease in hemoglobin of $2 g/dl or
bleeding leading to transfusion of $2 U of whole
blood or red blood cells. Clinically relevant nonmajor
bleeding was also assessed as a secondary endpoint in
the ﬁrst 72 h (10).
Other secondary safety outcomes included symp-
tomatic recurrent PE and mortality. For the diagnosis
of symptomatic recurrent PE, documentation of
clinical symptoms or signs suggesting recurrent PE
was required in combination with objective conﬁr-
mation with CTA, ventilation-perfusion lung scan-
ning, or pulmonary arteriography. Hemoglobin,
hematocrit, platelet count, activated partial throm-
boplastin time, international normalized ratio, bloodurea nitrogen, and creatinine were measured at
baseline or screening, within 4 h post-USCDT pro-
cedure, and at 48 h after the start of USCDT. A safety
monitor adjudicated all major bleeding events during
the study but was not blinded to the speciﬁc treat-
ment arms. The adjudication committee reviewed
diagnoses of symptomatic recurrent PE, and events
that occurred up to the 365-day follow-up visit are
reported.
STATISTICAL ANALYSIS. The intention-to-treat
(ITT) patient population comprised all randomized
patients. Unless otherwise speciﬁed, analyses were
performed for primary and secondary efﬁcacy end-
points for the ITT and modiﬁed-per-protocol (mPP)
population (Figure 1). Analyses were performed
separately for each treatment arm. Continuous mea-
sures are summarized as numbers, mean, SD, median,
minimum, and maximum. Categorical data are











Age, yrs 58.5 (31–74) 62.0 (29–77) 60.0 (36–77) 58.5 (29–76) 60.0 (29–77)
Sex
Female 12 (42.9) 12 (44.4) 17 (60.7) 7 (38.9) 48 (47.5)
Male 16 (57.1) 15 (55.6) 11 (39.3) 11 (61.1) 53 (52.5)
Race
Caucasian 16 (57.1) 14 (51.9) 19 (67.9) 11 (61.1) 60 (59.4)
African American 12 (42.9) 10 (37.0) 9 (32.1) 6 (33.3) 37 (36.6)
Hispanic or Latino 0 2 (7.4) 0 0 2 (2.0)
Asian or Paciﬁc Islander 0 1 (3.7) 0 0 1 (1.0)
Other§ 0 0 0 1 (5.6) 1 (1.0)
Weight, lbs 246.3  82.7 238.3  60.7 254.9  59.4 195.8  39.3 237.5  66.5
BMI, kg/m2 36.1  11.4 36.3  11.0 39.5  8.6 29.1  6.7 35.8  10.3
Congestive heart failure 2 (7.1) 4 (14.8) 4 (14.3) 1 (5.6) 11 (10.9)
Diabetes 11 (39.3) 10 (37.0) 11 (39.3) 3 (16.7) 35 (34.7)
Tobacco use 10 (35.7) 11 (40.7) 9 (32.1) 9 (50.0) 39 (38.6)
BMI $30 kg/m2 19 (67.9) 17 (63.0) 26 (92.9) 7 (38.9) 69 (68.3)
Previous PE 7 (25.0) 4 (14.8) 6 (21.4) 2 (11.1) 19 (18.8)
Previous DVT 11 (39.3) 10 (37.0) 14 (50.0) 11 (61.1) 46 (45.5)
Values are median (range), n (%), or mean  SD. *The intention-to-treat (ITT) patient population comprised all randomized patients; analyses were performed for primary and
secondary efﬁcacy endpoints for the ITT population. †Arm 1: ultrasound-facilitated catheter-directed thrombolysis (USCDT) for 2 h with tissue plasminogen activator (tPA)
infused at 2 mg/h per catheter (i.e., 4 mg per lung); arm 2: USCDT for 4 h with tPA infused at 1 mg/h per catheter (i.e., 4 mg per lung); arm 3: USCDT for 6 h with tPA infused at 1
mg/h per catheter (i.e., 6 mg per lung); arm 4: USCDT for 6 h with tPA infused at 2 mg/h per catheter (i.e., 12 mg per lung). ‡n¼ 27 for weight and body mass index (BMI) in arm
1, resulting in n ¼ 100 for weight and BMI in the column for all patients. §One patient reported race of black/white.
DVT ¼ deep vein thrombosis; PE ¼ pulmonary embolism.
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1405summarized as frequency and percentage for each
data category. Missing data were not imputed for the
efﬁcacy and safety analyses. Changes from baseline
(absolute and percentage change) were summarized
at 48 h with 95% conﬁdence intervals for mean
changes. Statistical signiﬁcance for changes from
baseline were assessed using the Student’s t-test.
EFFICACY ANALYSES. The primary efﬁcacy outcome
was change in RV-to-LV diameter ratio from baseline
to 48  6 h after the start of the USCDT procedure.
The main primary endpoint analyses reported are for
the ITT and mPP populations. For each treatment
arm, the post-procedural RV-to-LV diameter ratio was
compared with baseline. Assuming a standard devi-
ation of 0.41, as observed in the SEATTLE II study,
and a 1-sided p value of 0.15, 24 evaluable subjects
would provide 95% power in each arm to detect a
mean RV-to-LV diameter ratio reduction of 0.23 or
more. The power for simultaneous success in all 4
arms is approximately 0.81. A 1-sided p < 0.15
Student’s t-test rejecting the null hypothesis of no
reduction was regarded as a positive sign for further
investigating a treatment regimen. To limit the 4-arm
total false-positive error rate to 0.15, the Hochberg
procedure was used for statistical testing (11).
The main secondary efﬁcacy outcome reported is
change from baseline in pulmonary embolic burdenby reﬁned modiﬁed Miller score as assessed by CTA at
48 h after the start of the USCDT procedure (95%
conﬁdence intervals for mean changes). Statistical
signiﬁcance for changes from baseline were assessed
by Student’s t-test. This secondary analysis was also
performed for both the ITT and mPP populations.
SAFETY ANALYSES. The safety population included
patients in whom venous access was attempted spe-
ciﬁcally for USCDT. This population was used for all
safety analyses. For the primary safety analysis, the
number and percentage of subjects with major
bleeding events within 72 h of start of USCDT pro-
cedure were reported with a 95% Wilson conﬁdence
interval. The frequencies and proportions of patients
with symptomatic recurrent PE and death during the
30- and 365-day follow-up periods are reported with
95% Wilson score conﬁdence intervals.
RESULTS
We randomized 101 patients, and patient disposition is
shown in Figure 1. Baseline demographics are shown in
Table 1 and were similar across treatment groups,
although arm 3 had more women and arm 4 had lower
weight and body mass index than the other groups.
Presenting symptoms, signs, biomarkers, and leg ul-
trasound results are shown in Table 2. Seventy-nine











Dyspnea 24 (85.7) 24 (88.9) 27 (100.0) 18 (100.0) 94 (93.1)
Tachycardia† 15 (53.6) 9 (33.3) 13 (46.4) 5 (27.8) 42 (41.6)
Hypoxemia 5 (17.9) 9 (33.3) 7 (25.0) 4 (22.2) 25 (24.8)
Dizziness/lightheadedness 11 (39.3) 6 (22.2) 12 (42.9) 4 (22.2) 33 (32.7)
Syncope 4 (14.3) 5 (18.5) 6 (21.4) 5 (27.8) 20 (19.8)
Chest pain 15 (53.6) 11 (40.7) 13 (46.4) 8 (44.4) 47 (46.5)
Swollen lower extremity 5 (17.9) 5 (18.5) 7 (25.0) 4 (22.2) 21 (20.8)
Leg pain 8 (28.6) 3 (11.1) 3 (10.7) 4 (22.2) 18 (17.8)
DVT (ultrasound) 12 (42.9) 11 (40.7) 10 (35.7) 10 (55.6) 43 (42.6)
Elevated BNP or troponin I‡ 20 (77.0) 23 (92.0) 23 (82.0) 11 (61.0) 77 (79.0)
Elevated BNP and troponin I§ 9 (35.0) 8 (32.0) 6 (21.0) 5 (28.0) 28 (29.0)
Values are n (%). *The ITT patient population comprised all randomized patients; analyses were performed for
primary and secondary efﬁcacy endpoints for the ITT population. †Heart rate >100 beats/min. ‡Arm 1, n ¼ 26;
arm 2, n ¼ 25; arm 3, n ¼ 28; arm 4, n ¼ 18; all patients, N ¼ 97. §Arm 1, n ¼26; arm 2, n ¼ 25; arm 3, n ¼ 28; arm
4, n ¼ 18; all patients, N ¼ 96.
BNP ¼ B-type natriuretic peptide; other abbreviations as in Table 1.
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1406percent of patients were at intermediate or high risk
(abnormal right ventricle by echocardiography or CTA
and abnormal biomarkers). Randomization to arm 4
was stopped after an ICH developed that was consid-
ered probably related to thrombolytic therapy and
anticoagulation by the safety monitor. After review of
the medical records, the steering committee deter-
mined that the patient may have been at increased risk
for bleeding and required the protocol to be amended
to exclude patients with histories of any hematologic
disease likely to be associated with bleeding and to no
longer enroll in arm 4 (12 mg of tPA per lung over 6 h).
Of note, the concentration of tPA in the 24-mg infusion
in our study was higher than in the ULTIMA (6) and
SEATTLE II (7) trials (2 mg/h per catheter rather than 1TABLE 3 RV-to-LV Diameter Ratio by CTA
Arm
ITT population,* n 2
RV/LV diameter ratio at baseline 1.47 
Change from baseline at 48 h 0.40
Percentage change from baseline at 48 h 24.0
95% CI, % 30.5 t
p value† (2-sided Student’s t-test comparing with baseline) <0.0
mPP population,* n 2
RV/LV diameter ratio at baseline 1.51 
Change from baseline at 48 h 0.46
Percentage change from baseline at 48 h 26.9
95% CI 34.1 t
p value† (2-sided Student’s t-test comparing with baseline) <0.0
Values are mean  SD. *The intention-to-treat (ITT) patient population comprised all
endpoints for the ITT population. The modiﬁed-per-protocol (mPP) population comprise
additional thrombolytic therapy as rescue therapy. †The p value is given for change from
angiography (CTA). §n ¼ 27; 1 patient did not undergo follow-up CTA. kn ¼ 21; 1 patien
CI ¼ conﬁdence interval; LV ¼ left ventricular; RV ¼ right ventricular.mg/h per catheter), and our infusion rates were
shorter.
EFFICACY. Mean baseline RV-to-LV diameter ratio
(Table 3) and mean reﬁned modiﬁed Miller score
improved from baseline in both the ITT and mPP
populations. The patients treated with bilateral
catheters had slightly higher but similar baseline RV-
to-LV diameter ratios as those treated with unilateral
catheters. In both the ITT and mPP populations, there
was a stepwise reduction in reﬁned modiﬁed Miller
score (Table 4).
SAFETY. Bleeding . No major bleeding events
occurred in arm 1 during the 72 h after the start of the
USCDT procedure. In the other study arms, 4 patients
had a total of 5 major bleeding events. Two of these
patients received additional tPA beyond that desig-
nated by randomization after study treatment
(Table 5). In arm 2, a 61-year-old woman developed
anemia and ICH. Syncope resulted in facial trauma
and anemia; the latter was considered related to the
thrombolytic agent administered as USCDT. The
USCDT procedure led to a signiﬁcantly improved RV-
to-LV diameter ratio. However, she developed prob-
able recurrent PE causing hypotension 48 h after
USCDT treatment and received a rapid infusion of 50
mg of intravenous tPA, which was followed by a
nonfatal ICH, believed precipitated by the systemic
tPA. At 2 years, she is alive, with mild right-hand
neurological deﬁcit (incoordination). In arm 3, a 35-
year-old woman developed anemia in the setting of
a bleeding uterine ﬁbroid after receiving an addi-
tional 12 mg of tPA, beyond the assigned 12 mg. The
anemia was likely related to or exacerbated by tPA. In1 Arm 2 Arm 3 Arm 4
7 27 28 18
0.39 1.43  0.33 1.49  0.37 1.51  0.58
 0.37 0.35  0.27 0.42  0.32 0.48  0.51
 15.9‡ 22.6  14.1‡ 26.3  16.8§ 25.5  22.7
o 17.6 28.3 to 16.9 32.9 to 19.7 36.8 to 14.2
001 <0.0001 <0.0001 0.0011
2 21 24 16
0.40 1.52  0.31 1.51  0.36 1.55  0.60
 0.38 0.40  0.27 0.44  0.32 0.52  0.52
 15.9k 24.8  13.5 26.9  16.3 27.26  21.6
o 19.6 30.9 to 18.7 33.8 to 20.1 38.8 to 15.7
001 <0.0001 <0.0001 0.0013
randomized patients; analyses were performed for primary and secondary efﬁcacy
d randomized patients who were treated with bilateral catheters and did not receive
baseline to 48 h. ‡n ¼ 26; 1 patient did not undergo follow-up computed tomographic
t did not undergo follow-up CTA.
TABLE 4 Reﬁned Modiﬁed Miller Score by CTA
Arm 1 Arm 2 Arm 3 Arm 4
ITT population,* n 27 27 28 18
Baseline 20.33  2.99 19.70  4.62 21.14  2.37 20.44  4.12
Percentage change from baseline at 48 h 5.5  9.0‡ 9.2  10.6§ 14.0  11.7§ 25.7  26.0
95% CI, % 9.3 to 1.7 13.4 to 4.9 18.7 to 9.2 38.6 to 12.8
p value† (1-sided) 0.0032 <0.0001 <0.0001 0.0003
mPP population,* n 22 21 24 16
Baseline 20.68  1.73 20.95  2.11 21.29  1.30 21.06  2.43
Percentage change from baseline at 48 h 6.0  10.0k 9.0  9.9 12.5  11.0¶ 21.7  24.7
95% CI, % 10.8 to 1.2 13.5 to 4.5 17.2 to 7.7 34.9 to 8.6
p value† (1-sided) 0.0085 0.0002 <0.0001 0.0016
Values are mean  SD. *The ITT patient population comprised all randomized patients; analyses were performed for primary and secondary efﬁcacy endpoints for the ITT
population. The mPP population comprised randomized patients who were treated with bilateral catheters and did not receive additional thrombolytic therapy as rescue
therapy. †The p value is given for percentage change from baseline at 48 h. ‡n ¼ 24. §n ¼ 26. kn ¼ 19. ¶n ¼ 23. See Online Appendix.
Abbreviations as in Tables 1 and 3.
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1407arm 4, 2 patients each had an event considered
related to thrombolysis: a 73-year-old man with hy-
pertension developed ICH and died 11 days after
USCDT while in a rehabilitation facility. His platelet
count was low normal at 133,000/ml at admission, and
there was a history of pancytopenia. He developed
hypertension to 181/92 mm Hg after USCDT. The head
computed tomographic scan revealing the ICH sug-
gested the possibility of an arteriovenous malforma-
tion. Another patient had bleeding after USCDT from
a splenic pseudoaneurysm treated with coil emboli-
zation with full recovery. Seven patients developed
clinically relevant nonmajor bleeding (medical inter-
vention required) in the ﬁrst 72 h, including 2 with
bleeding or hematoma at the USCDT insertion site, 1
bleeding from the venous sheath after placement of
an RV assist device, 2 cases of hematuria, 1 case of
epistaxis, and 1 scalp laceration.
Recurrent PE . Symptomatic recurrent PE conﬁrmed
by CTA occurred in 1 patient (1%) in arm 3, 18 days
after the index event. He was not anticoagulated at
the time, because he had not ﬁlled his anticoagulation
prescription.TABLE 5 Major Bleeding Within 72 h (Primary Safety Endpoint)
Safety Population* mPP*
n n (%) Events (%) n n (%) Events (%)
Arm 1 27 0 (0) 0 (0) 22 0 (0) 0 (0)
Arm 2 27 1 (3.7) 2 (7.4) 21 1 (4.7)† 1 (4.7)†
Arm 3 28 1 (3.6) 1 (3.6) 24 0 (0) 0 (0)
Arm 4 18 2 (11.1) 2 (11.1) 16 2 (11.1) 2 (11.1)
All patients 100 4 (4) 5 (5) 83 3 (3.6) 3 (3.6)
*See text for deﬁnition of safety and mPP populations and details of major
bleeding cases. †A major bleeding event of anemia is included here even though
the patient subsequently received systemic tPA and had a second major bleeding
event, which excluded her from the mPP population.
Abbreviations as in Tables 1 and 3.Morta l i ty . One patient (1%) died during the initial 30
days. The estimated 365-day mortality rate was 2% by
the Kaplan-Meier method, which accounts for cases
that were withdrawn and lost to follow-up. (Table 6).
DISCUSSION
In OPTALYSE PE (A Randomized Trial of the Optimum
Duration of Acoustic Pulse Thrombolysis Procedure in
Acute Intermediate-Risk Pulmonary Embolism) trial,
USCDT with lower doses of thrombolytic therapy
ranging from 4 to 12 mg per lung and shorter infusion
times (2 to 6 h) than previously studied in
intermediate-risk PE patients was associated with
statistically signiﬁcant improvement in RV-to-LV
diameter ratio (the primary endpoint) for all arms in
the ITT and mPP populations, compared with base-
line. The RV-to-LV diameter ratio improved in each of
the 4 arms by approximately 25%. The reﬁned modi-
ﬁed Miller score also statistically improved from
baseline in each arm in both ITT and mPP patients,
although the improvement increased as the tPA dose
and infusion duration increased. Most patients (86%)
underwent treatment of both lungs (2 catheters). Pa-
tients in whom 1 lung (1 catheter) was treated were
equally divided among the 4 arms, and the numbers
were too small to meaningfully analyze separately.
The major bleeding rate was 4.0% for the ITT pop-
ulation and 3.6% for the mPP group, 1 of which was an
ICH. This event appeared related to USCDT. A second
ICH occurred after delivery of systemic tPA 50 mg for
probable recurrent massive PE and was likely due to
the subsequent systemic thrombolysis. There were no
ICH events in the ULTIMA and SEATTLE II trials and 2
such events in OPTALYSE PE trial (6,7). Thus, in the 277
patients in these 3 USCDT trials, the ICH event rate was
0.72%, with only 1 attributable to USCDT (0.36%).
TABLE 6 All-Cause Mortality and Recurrent Pulmonary Embolism in Safety Population*
n
All-Cause Mortality Conﬁrmed Recurrent PE Suspected Recurrent PE
Within 30 Days Within 365 Days Within 30 Days Within 365 Days Within 30 Days Within 365 Days
Arm 1 27 0 (0) 1 (3.7)† 0 (0) 0 (0) 0 (0) 0 (0)
Arm 2 27 0 (0) 0 (0) 0 (0) 1 (3.7) 1 (3.7)‡ 1 (3.7)‡
Arm 3 28 0 (0) 0 (0) 1 (3.6) 1 (3.6) 0 (0) 0 (0)
Arm 4 18 1 (5.6)§ 1 (5.6)§ 0 (0) 0 (0) 0 (0) 0 (0)
All patients 100 1 (1) 2 (2k) 1 (1) 2 (2) 1 (1) 1 (1)
Values are n (%). *At 30 days, 2 patients were lost to follow-up, 1 had died, and 1 had withdrawn; thus, 96 patients were assessed for safety through 30 days. At 1-year follow-
up, 1 more patient had withdrawn (total 2), and 1 more had died (total 2). Although 13 more were lost to follow-up (total 15), 12 of the 15 were conﬁrmed alive at 365 days.
†Patient death attributed to complications of chronic obstructive pulmonary disease and multiple organ failure 177 days after USCDT. PE noted on imaging but believed to be
chronic by adjudication committee. ‡Subject was symptomatic, but no diagnostic imaging was collected before treatment with systemic tissue-type plasminogen activator for
suspected recurrent massive PE. §Death was attributed to cardiac arrest. No follow-up imaging or autopsy was performed to rule out recurrent PE. kEstimated mortality rate
was 2% by Kaplan-Meier method.
Abbreviations as in Table 1.
Tapson et al. J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 1 1 , N O . 1 4 , 2 0 1 8
USCDT for Acute Intermediate-Risk PE J U L Y 2 3 , 2 0 1 8 : 1 4 0 1 – 1 0
1408We believed that the RV-to-LV diameter ratio serves
as a reproducible and well-validated tool for identi-
fying patients with PE at risk for adverse outcomes,
including increased 30-day mortality (12–14). There-
fore, we chose change in the RV-to-LV diameter ratio
as our primary endpoint. We are not certain why the
RV-to-LV diameter ratio improved similarly across all
arms, while the reﬁned modiﬁed Miller score repre-
senting clot burden improved as the dose increased
and the infusion duration increased. This observation
suggests that there is not a direct correlation between
the pulmonary arterial embolic burden and RV dila-
tion. Perhaps relatively low doses of thrombolytic
agents can improve functional vessel radius enough to
improve pulmonary perfusion (Poiseuille’s law) (15)
and thus RV-to-LV diameter ratio, but to produce a
similar reduction in overall clot burden, higher doses
or longer infusions of thrombolytic are required.
The rate of recurrent PE in this trial was 1% at 30
days (1 patient conﬁrmed), which is similar to the rate
reported with standard anticoagulation (16). This
observation emphasizes the need to be vigilant with
outpatient follow-up, because our patient who expe-
rienced recurrent PE had not ﬁlled his prescription for
anticoagulant medication.
STUDY LIMITATIONS. Limitations of our study
include the relatively small number of patients in
each arm. However, we had a combined group of 100
patients undergoing USCDT, and all arms demon-
strated statistically signiﬁcant improvement in both
RV-to-LV diameter ratio and reﬁned modiﬁed Miller
score. The absence of a heparin control was a limita-
tion. Although the ULTIMA trial (head-to-head USCDT
vs. heparin) proved that USCDT results in more rapid
improvement in RV-to-LV diameter ratio (and pul-
monary artery pressure) than anticoagulation alone,
the endpoint was 24 h, not 48 h as in our study. Thus,
we cannot rule out that continued anticoagulationand endogenous thrombolysis contributed to the
improved RV-to-LV diameter ratio and reﬁned modi-
ﬁed Miller score at 48 h. Furthermore, there has been
no head-to-head comparison of USCDT with other
delivery catheters, and the lack of a standard catheter
thrombolytic infusion arm was a limitation. Although
this would have been ideal, we did not have the re-
sources to include such an arm.
A primary strength of the study included the use of
lower doses of tPA delivered over a shorter period than
traditionally studied. The randomized design was also
important in minimizing bias, which, for example,
might have favored administering higher doses or
longer infusions of tPA to patients with higher RV-to-
LV diameter ratios or higher reﬁned modiﬁed Miller
score values. Another strength was including the
reﬁned modiﬁed Miller score as a secondary endpoint,
demonstrating that RV-to-LV diameter ratio can
improve signiﬁcantly even without a substantial
(although still a statistically signiﬁcant) improvement
in obstruction score. Importantly, all imaging studies
were read by a central laboratory in a blinded manner,
without knowledge of tPA dose or infusion duration.
Our study demonstrated that lower doses of tPA
than previously studied with USCDT were associated
with favorable improvement in RV-to-LV diameter
ratio and with low major bleeding rates. This is
consistent with data suggesting that lower doses of
systemic tPA also achieve favorable results, with less
bleeding (17). In intermediate-risk PE, it has been
shown that RV-to-LV diameter ratio is improved at 24
h with USCDT compared with anticoagulation alone
(6) and is associated with improvement at 48 h
compared with baseline in intermediate-risk patients
and in a small population of massive PE (7) patients,
with a low major bleeding rate without ICH.
There remains a paucity of high-quality random-
ized trials of catheter-directed thrombolysis with
PERSPECTIVES
WHAT IS KNOWN? Acute intermediate-risk PE patients are
critically important to study because they are common in clinical
practice and because the parameters that deﬁne them, including
abnormal RV function and elevated B-type natriuretic peptide
and troponin, are associated with increased mortality. USCDT
using doses of tPA in the range of 20 to 24 mg delivered over 12
to 24 h has been associated with improved RV-to-LV diameter
ratio within 24 to 48 h, although improved mortality has not
been demonstrated.
WHAT IS NEW? Lower doses of tPA and shorter infusion du-
rations than previously studied appear to be safe and effective in
acute intermediate-risk PE patients with improved RV-to-LV
diameter ratio and reduced clot burden demonstrated at 48 h.
WHAT IS NEXT? Future clinical trials should focus on carefully
selected acute intermediate- and high-risk patients with goals of
reﬁning the ideal USCDT regimen. These trials should include
comparator groups of anticoagulation alone, systemic ﬁbrino-
lysis, or other catheter-based techniques focusing on very short-
term as well as longer-term clinical outcomes, which will be
critical in deﬁning how USCDT should be applied to patients with
acute PE. Registries that include “real-world data” may com-
plement such research.
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1409adequate controls in acute PE (18–20). Such trials are
needed to determine short- and long-term beneﬁt, to
identify patients most likely to beneﬁt, and to learn
whether this strategy prevents adverse long-term
outcomes such as post-PE syndrome and chronic
thromboembolic pulmonary hypertension. Future
trials examining other clinical endpoints should also
be considered (21). Studies examining health care
costs and outcomes, such as hemodynamic deterio-
ration and quality of life, will also inform the optimal
use of this technology (22).
CONCLUSIONS
We have demonstrated that USCDT using lower doses
and shorter infusions of thrombolytic therapy in
acute intermediate-risk PE is associated with an
improvement in RV-to-LV diameter ratio as well as a
reduction in clot burden at 48 h. We believe that
USCDT using lower dose and shorter infusion regi-
mens has potential in this setting and should be
further studied and reﬁned in future trials.
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APPENDIX For the calculation of pulmonary
embolism burden (obstruction score), please
see the online version of this paper.
